Pharmig Secretary General Alexander Herzog criticizes the health insurance companies for using incorrect figures regarding medication expenditures and warns of a potential crisis in the European pharmaceutical industry, while emphasizing that discounts are pointless and that high development costs and national differences in price negotiations result in many medications not being brought to market in Austria. (translated)
GLP-1 drugs, such as Ozempic and Wegovy, show unexpected effects, not only limiting appetite and supporting weight loss but also affecting heart health, inflammation, and addiction risk, which requires further research to better understand their full impact on the body. (translated)
Nieuw 'Briefje van Jan' - aan Sophie Hermans "Beste Sophie, Ik geloof zelfs dat Angela de Jong tegenwoordig de redactie van het Algemeen Dagblad niet meer binnengerold hoeft te worden, maar gewoon weer zelf naar binnen kan wandelen..." https://t.co/fzSbhojFPl #ozempic #wegovy #mounjaro #boetes #media #briefjevanjan #media #briefjevanjan #nieuws
The Dutch Health and Youth Inspectorate (IGJ) has imposed fines of tens of thousands of euros on Dutch newspapers, including NRC and de Volkskrant, for overly promotional reporting about the medications Ozempic, Wegovy, and Mounjaro, which the media claims is an infringement on press freedom. (translated)
Dutch media, including NRC, de Volkskrant, AD, and De Telegraaf, have been fined tens of thousands of euros for their reporting on weight loss medications such as Ozempic and Wegovy, as the Health and Youth Care Inspectorate (IGJ) considers these articles to be public advertising, and the editors-in-chief fear that this puts press freedom under pressure. (translated)
In Germany, a new weight loss medication in tablet form containing the active ingredient Semaglutide will be available for the first time starting September 1, 2026, which is approved for weight reduction in individuals with obesity or overweight, although it will only be available by prescription and the costs will initially have to be borne by the patients themselves. (translated)
Matthias Blüher discusses in an interview the newly introduced weight loss tablet Wegovy, which could significantly reduce barriers for patients in obesity treatment, but warns of uncertainties regarding its effects and side effects, and emphasizes the need for prioritized care for high-risk patients in the context of health policy and current legislative barriers in Germany. (translated)
Novo Nordisk presents with the arrival of Wegovy in tablet form, which will be available from September 1 in Germany, a revolution in weight loss for millions of people who are trying to lose weight and prefer an alternative to injections, while discussing effectiveness, daily use, side effects, and the future of treatment. (translated)
GLP-1 drugs, such as Ozempic and Wegovy, not only aid weight loss by reducing appetite, but they can also limit cravings for alcohol and other addictive substances, which is related to their action on brain areas responsible for regulating desires. (translated)
Pharmaceutical company Novo Nordisk will launch Wegovy tablets on the German market on September 1, 2026, which contain the same active ingredient Semaglutide as the currently available injectable forms, thus offering an alternative option for customers who avoid injections. (translated)
The Danish pharmaceutical group Novo Nordisk plans to introduce its weight loss pill Wegovy to the German market, while the company's shares are facing a decline due to investors' disappointment over slightly lower revenues and delays in clinical trials of new drugs. (translated)
The article discusses the possibility that statutory health insurance companies in Germany could start covering the costs of obesity medications like Wegovy and Mounjaro, which are currently considered lifestyle products and are usually paid for by patients themselves, while the new chairwoman of G-BA, Sonja Optendrenk, indicated that it might be reasonable to change regulations and recognize these medications as part of treatment. (translated)
The European Commission has approved the drug Wegovy in tablet form as the first oral medication intended for the treatment of obesity, which is a significant step in the fight against overweight and obesity in the countries of the European Union. (translated)
The European Commission has approved the first oral GLP-1 medication, Wegovy, which aims to help treat obesity and overweight, providing patients with a new, more convenient method of therapy, confirmed by clinical trial results. (translated)
Un nou studiu realizat de cercetători de la Universitatea din Pennsylvania relevă că medicamentele pentru slăbit din clasa agoniștilor receptorilor GLP-1, precum Mounjaro, Ozempic și Wegovy, sunt asociate cu un risc semnificativ mai mare de cădere a părului, cu până la 68% comparativ cu alte tratamente, sugerând că efectele secundare ar putea fi legate de pierderea rapidă în greutate și deficiențe de nutrienți esențiali. #caderapărului #medicamente #slăbit
Un studiu recent realizat de cercetătorii de la Universitatea din Pennsylvania a descoperit o legătură între utilizarea medicamentelor pentru slăbit și diabet, cum ar fi Ozempic, Wegovy și Mounjaro, și o ușoară creștere a riscului de cădere a părului, deși probabilitatea generală de a experimenta acest efect secundar rămâne relativ mică. #caderapărului #medicamente #diabet
Iako lijekovi za mršavljenje iz skupine GLP-1, poput Ozempica i Wegovyja, nude značajne rezultate u borbi protiv pretilosti, novo istraživanje ukazuje na zabrinjavajuću nuspojavu – povećani rizik od gubitka kose, osobito alopecije, što može biti povezano s brzim gubitkom tjelesne mase i nedostatkom hranjivih tvari. #glp1 #gubitakkose #lijekovizamiršavljenje
Obesity treatment: The Danish pharmaceutical giant Novo Nordisk, manufacturer of Wegovy and Ozempic, is suing the laboratory Eli Lilly, maker of Mounjaro, for "false advertising." (translated)
Die EU hat die erste orale „Abnehmpille“ mit dem Wirkstoff Semaglutid zugelassen, die ähnlich wie die bisherige Abnehmspritze funktioniert und für Menschen mit starkem Übergewicht oder Übergewicht mit Begleiterkrankungen vorgesehen ist, jedoch tägliche Einnahme erfordert und unter ärztlicher Begleitung erfolgen sollte. #Abnehmpille #Wegovy #Übergewicht
Novo Nordisk ha demandado a Eli Lilly en Estados Unidos por publicidad engañosa, acusando a su competidor de utilizar estudios desactualizados para afirmar que sus medicamentos para la pérdida de peso son más efectivos que Ozempic y Wegovy, solicitando además la prohibición de dichos anuncios y compensación económica. #NovoNordisk #Ozempic #EliLilly
